NTRANatera Inc

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (CytoDyn), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Companys board of directors. Tom and Eric have helped lead some of the most important advances in modern oncology, and we are...

read more...

Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge response.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration...

NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionAL (SIGNAL)-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early-stage...

NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand keeps surging.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the companys novel SNP-informed deep sequencing technology, Panorama NIPT is now backed by...